ArticleThe Journal of infectious diseases2014
The survival benefits of antiretroviral therapy in South Africa.
Article in The Journal of infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Optimal management of cervical cancer in HIV-positive patients: a systematic review.Cancer medicine · 2015Pooled it
- Potential Clinical and Economic Impacts of Cutbacks in the President's Emergency Plan for AIDS Relief Program in South Africa : A Modeling Analysis.Annals of internal medicine · 2025Article
- The impact of tobacco smoking and smoking cessation on lung cancer and stroke incidence among people with HIV on antiretroviral therapy in South Africa: a simulation modeling study.BMJ global health · 2024Article
- Entangled Connections: HIV and HPV Interplay in Cervical Cancer-A Comprehensive Review.International journal of molecular sciences · 2024Review
- Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study.Journal of the International AIDS Society · 2024Article
- Hepatitis B Virus Research in South Africa.Viruses · 2022Review
- Cervical Cancer Treatment in HIV-Positive Patients: A Survey of Treatment Practices in India.JCO global oncology · 2021Article
- Retention in Care Trajectories of HIV-Positive Individuals Participating in a Universal Test-and-Treat Program in Rural South Africa (ANRS 12249 TasP Trial).Journal of acquired immune deficiency syndromes (1999) · 2019Article
- A systematic review and cost-effectiveness analyses of the new World Health Organization guidelines for the treatment of HIV-positive adults in India.Medical journal, Armed Forces India · 2019Article
- The Impact of Anti-Retroviral Therapy on Tuberculosis Detection at the National Level in South Africa.The American journal of tropical medicine and hygiene · 2018Article
- Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.AIDS research and human retroviruses · 2018Article
- Rapid Accurate Identification of Tuberculous Meningitis Among South African Children Using a Novel Clinical Decision Tool.The Pediatric infectious disease journal · 2018Article
- Human immunodeficiency virus infection in breast cancer patients: The prevalence thereof and its effect on breast cancer characteristics at Dr. George Mukhari Academic Hospital Breast Clinic, Ga-Rankuwa, South Africa.SA journal of radiology · 2018Article
- Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.Open forum infectious diseases · 2017Article
- "I Have to Push Him with a Wheelbarrow to the Clinic": Community Health Workers' Roles, Needs, and Strategies to Improve HIV Care in Rural South Africa.AIDS patient care and STDs · 2016Article
- The History of the HIV/AIDS Epidemic in Africa.Current HIV/AIDS reports · 2016Review
- Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.The Journal of infectious diseases · 2016Article
- Survival benefits of antiretroviral therapy in Brazil: a model-based analysis.Journal of the International AIDS Society · 2016Article
- Southern Africa: the Highest Priority Region for HIV Prevention and Care Interventions.Current HIV/AIDS reports · 2015Article
- Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
backgroundWe sought to quantify the survival benefits attributable to antiretroviral therapy (ART) in South Africa since 2004.
methodsWe used the Cost-Effectiveness of Preventing AIDS Complications-International model (CEPAC) to simulate 8 cohorts of human immunodeficiency virus (HIV)-infected patients initiating ART each year during 2004-2011. Model inputs included cohort-specific mean CD4(+) T-cell count at ART initiation (112-178 cells/µL), 24-week ART suppressive efficacy (78%), second-line ART availability (2.4% of ART recipients), and cohort-specific 36-month retention rate (55%-71%). CEPAC simulated survival twice for each cohort, once with and once without ART. The sum of the products of per capita survival differences and the total numbers of persons initiating ART for each cohort yielded the total survival benefits.
resultsLifetime per capita survival benefits ranged from 9.3 to 10.2 life-years across the 8 cohorts. Total estimated population lifetime survival benefit for all persons starting ART during 2004-2011 was 21.7 million life-years, of which 2.8 million life-years (12.7%) had been realized by December 2012. By 2030, benefits reached 17.9 million life-years under current policies, 21.7 million life-years with universal second-line ART, 23.3 million life-years with increased linkage to care of eligible untreated patients, and 28.0 million life-years with both linkage to care and universal second-line ART.
conclusionsWe found dramatic past and potential future survival benefits attributable to ART, justifying international support of ART rollout in South Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.